Genmab A/S Genmab To Present At Morgan Stanley 19th Annual Global Healthcare Conference
27 August 2021 - 6:42PM
UK Regulatory
TIDMGEN
Media Release
Copenhagen, Denmark, 27 August, 2021
https://www.globenewswire.com/Tracker?data=eac0nXg-9zwI3qYovvB4U3vUvLSp7v5rVgRvbEIoyYTyXpn2vMydSQW1rSM6CrEcvjih8IPBIUX3XCqspv1yOw==
Genmab A/S (Nasdaq: GMAB) announced today that its CEO, Jan van de
Winkel, Ph.D. will participate in a virtual fireside chat at the
Morgan Stanley 19th Annual Global Healthcare Conference at 8:00 AM
EDT / 2:00 PM CEST on September 9, 2021. A webcast of the event,
which will include brief opening remarks followed by a
question-and-answer session, will be available on Genmab's website
at https://ir.genmab.com/events-and-presentations#content
About Genmab
Genmab is an international biotechnology company with a core
purpose to improve the lives of patients with cancer. Founded in
1999, Genmab is the creator of multiple approved antibody
therapeutics that are marketed by its partners. The company aims to
create, develop and commercialize differentiated therapies by
leveraging next-generation antibody technologies, expertise in
antibody biology, translational research and data sciences and
strategic partnerships. To create novel therapies, Genmab utilizes
its next-generation antibody technologies, which are the result of
its collaborative company culture and a deep passion for
innovation. Genmab's proprietary pipeline consists of modified
antibody candidates, including bispecific T-cell engagers and
next-generation immune checkpoint modulators, effector function
enhanced antibodies and antibody-drug conjugates. The company is
headquartered in Copenhagen, Denmark with locations in Utrecht, the
Netherlands, Princeton, New Jersey, U.S. and Tokyo, Japan. For more
information, please visit Genmab.com
https://www.globenewswire.com/Tracker?data=eac0nXg-9zwI3qYovvB4U1MCLbaCt1kjvZPbaSIGsM5Lz0K9u3V7p6vzLF65vnXSUYYSzWb1FFciilngDujpag==
.
Contact:
Marisol Peron, Senior Vice President, Global Investor Relations
& Communications
T: +1 609 524 0065; E: mmp@genmab.com
https://www.globenewswire.com/Tracker?data=7dXYHL7JMRQfXxaicYCVaN6B2kcRNqp2v2U6nnbpN4etkLZPh1Y1joz5fnBWn7GZyDVOZKtDUQb--v99MWX_FQ==
For Investor Relations:
Andrew Carlsen, Vice President, Head of Investor Relations
T: +45 3377 9558; E: acn@genmab.com
https://www.globenewswire.com/Tracker?data=HcDUrWYXUCsMWbbPUDq4_y2R6z2f7GyTPUlLMu79DDE05dCAaf_VCNSzHOQqBuGgeVqygqNTocdsR3kKDasriw==
This Media Release contains forward looking statements. The
words "believe", "expect", "anticipate", "intend" and "plan" and
similar expressions identify forward looking statements. Actual
results or performance may differ materially from any future
results or performance expressed or implied by such statements. The
important factors that could cause our actual results or
performance to differ materially include, among others, risks
associated with pre-clinical and clinical development of products,
uncertainties related to the outcome and conduct of clinical trials
including unforeseen safety issues, uncertainties related to
product manufacturing, the lack of market acceptance of our
products, our inability to manage growth, the competitive
environment in relation to our business area and markets, our
inability to attract and retain suitably qualified personnel, the
unenforceability or lack of protection of our patents and
proprietary rights, our relationships with affiliated entities,
changes and developments in technology which may render our
products or technologies obsolete, and other factors. For a further
discussion of these risks, please refer to the risk management
sections in Genmab's most recent financial reports, which are
available on
https://www.globenewswire.com/Tracker?data=kUxvsv2ErAV6bl7tA0h-K0UmLM54dGy3_bpB0Ui0AILsxuM5_12yd5JjlSKgOaQnJiICE7BQtgh7uV2-ilm5Ig==
www.genmab.com and the risk factors included in Genmab's most
recent Annual Report on Form 20-F and other filings with the U.S.
Securities and Exchange Commission (SEC), which are available at
https://www.globenewswire.com/Tracker?data=kUxvsv2ErAV6bl7tA0h-K3_Is00NoUfYPU7guY-SxysD-3CJb1IDzN4Z6flApQIuHrdhy8TXpB-GGBbZLIAG4vqPoK7t6gl9EuphimelxRQ=
www.sec.gov. Genmab does not undertake any obligation to update or
revise forward looking statements in this Media Release nor to
confirm such statements to reflect subsequent events or
circumstances after the date made or in relation to actual results,
unless required by law.
Genmab A/S and/or its subsidiaries own the following trademarks:
Genmab(R) ; the Y-shaped Genmab logo(R) ; Genmab in combination
with the Y-shaped Genmab logo(R) ; HuMax(R) ; DuoBody(R) ; DuoBody
in combination with the DuoBody logo(R) ; HexaBody(R) ; HexaBody in
combination with the HexaBody logo(R) ; DuoHexaBody(R) and
HexElect(R) .
Media Release no. 08
CVR no. 2102 3884
LEI Code 529900MTJPDPE4MHJ122
Genmab A/S
Kalvebod Brygge 43
1560 Copenhagen V
Denmark
Attachment
-- 210827_MR08_morgan stanley
https://ml-eu.globenewswire.com/Resource/Download/4a123aac-d699-465a-a3ed-5bfb9b554856
(END) Dow Jones Newswires
August 27, 2021 04:42 ET (08:42 GMT)
Copyright (c) 2021 Dow Jones & Company, Inc.
Genuit (LSE:GEN)
Historical Stock Chart
From Mar 2024 to Apr 2024
Genuit (LSE:GEN)
Historical Stock Chart
From Apr 2023 to Apr 2024